Los Angeles Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Los Angeles Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Hold	295	–	–	﹤0.01%	2295
2026 Q1	$2.26K	Sell	295 -620	-68%	-$5.75K	﹤0.01%	2270
2025 Q4	$7.87K	Buy	+915	New	+$9.31K	﹤0.01%	2160
2025 Q3	–	Sell	-13,465	Closed	-$92.6K	–	1423
2025 Q2	$92.6K	Buy	+13,465	New	+$72K	﹤0.01%	1257
2024 Q3	–	Sell	-21,038	Closed	-$130K	–	1213
2024 Q2	$130K	Buy	+21,038	New	+$159K	﹤0.01%	1149
2021 Q1	–	Sell	-20,757	Closed	-$243K	–	1605
2020 Q4	$243K	Sell	20,757 -10,713	-34%	-$121K	﹤0.01%	1437
2020 Q3	$250K	Buy	31,470 +15,891	+102%	+$191K	﹤0.01%	1327
2020 Q2	$285K	Buy	15,579 +4,950	+47%	+$77.9K	﹤0.01%	1298
2020 Q1	$127K	Buy	+10,629	New	+$170K	﹤0.01%	1269

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Los Angeles Capital Management's FULC Position: Q2 2026 in Review

Los Angeles Capital Management held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 295 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Los Angeles Capital Management first reported a position in FULC in Q1 2020 and has held it in 9 quarters since. The position peaked at $285K in Q2 2020. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Los Angeles Capital Management held 295 shares of Fulcrum Therapeutics worth $1.08K as of Q2 2026.
Los Angeles Capital Management left its Fulcrum Therapeutics share count unchanged in Q2 2026.
Fulcrum Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2295 holding.
Los Angeles Capital Management first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 9 quarters since.
Los Angeles Capital Management's Fulcrum Therapeutics position peaked at $285K in Q2 2020.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.